Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence
Автор: ecancer
Загружено: 2022-11-29
Просмотров: 17
Описание:
Dr Mohamad Allaf, speaks to ecancer about his phase 3 randomised open label trial comparing perioperative nivolumab versus observation in patients with RCC undergoing nephrectomy.
In the investigational arm, nivolumab was administered (480mg IV q4 weeks) with 1 dose prior to surgery followed by 9 adjuvant doses. The control arm was surgery followed by surveillance without a placebo. Baseline tumour biopsy was required only in the nivolumab arm.
The results demonstrated perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence. OS data remains immature but is not statistically different between arms.
Subset analyses including risk stratification by pathologic stage are ongoing.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
